TY - JOUR
T1 - Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction
T2 - A collaborative meta-analysis
AU - Delewi, Ronak
AU - Hirsch, Alexander
AU - Tijssen, Jan G.
AU - Schächinger, Volker
AU - Wojakowski, Wojciech
AU - Roncalli, Jérôme
AU - Aakhus, Svend
AU - Erbs, Sandra
AU - Assmus, Birgit
AU - Tendera, Michal
AU - Goekmen Turan, R.
AU - Corti, Roberto
AU - Henry, Tim
AU - Lemarchand, Patricia
AU - Lunde, Ketil
AU - Cao, Feng
AU - Huikuri, Heikki V.
AU - Sürder, Daniel
AU - Simari, Robert D.
AU - Janssens, Stefan
AU - Wollert, Kai C.
AU - Plewka, Michal
AU - Grajek, Stefan
AU - Traverse, Jay H.
AU - Zijlstra, Felix
AU - Piek, Jan J.
PY - 2014/4
Y1 - 2014/4
N2 - AimsThe objective of the present analysis was to systematically examine the effect of intracoronary bone marrow cell (BMC) therapy on left ventricular (LV) function after ST-segment elevation myocardial infarction in various subgroups of patients by performing a collaborative meta-analysis of randomized controlled trials.Methods and resultsWe identified all randomized controlled trials comparing intracoronary BMC infusion as treatment for ST-segment elevation myocardial infarction. We contacted the principal investigator for each participating trial to provide summary data with regard to different pre-specified subgroups [age, diabetes mellitus, time from symptoms to percutaneous coronary intervention, infarct-related artery, LV end-diastolic volume index (EDVI), LV ejection fraction (EF), infarct size, presence of microvascular obstruction, timing of cell infusion, and injected cell number] and three different endpoints [change in LVEF, LVEDVI, and LV end-systolic volume index (ESVI)].Data from 16 studies were combined including 1641 patients (984 cell therapy, 657 controls). The absolute improvement in LVEF was greater among BMC-treated patients compared with controls: [2.55% increase, 95% confidence interval (CI) 1.83-3.26, P < 0.001]. Cell therapy significantly reduced LVEDVI and LVESVI (-3.17 mL/m2, 95% CI: -4.86 to -1.47, P < 0.001; -2.60 mL/m2, 95% CI -3.84 to -1.35, P < 0.001, respectively). Treatment benefit in terms of LVEF improvement was more pronounced in younger patients (age <55, 3.38%, 95% CI: 2.36-4.39) compared with older patients (age ≥55 years, 1.77%, 95% CI: 0.80-2.74, P = 0.03). This heterogeneity in treatment effect was also observed with respect to the reduction in LVEDVI and LVESVI. Moreover, patients with baseline LVEF <40% derived more benefit from intracoronary BMC therapy. LVEF improvement was 5.30%, 95% CI: 4.27-6.33 in patients with LVEF <40% compared with 1.45%, 95% CI: 0.60 to 2.31 in LVEF ≥40%, P < 0.001. No clear interaction was observed between other subgroups and outcomes.ConclusionIntracoronary BMC infusion is associated with improvement of LV function and remodelling in patients after ST-segment elevation myocardial infarction. Younger patients and patients with a more severely depressed LVEF at baseline derived most benefit from this adjunctive therapy. Published on behalf of the European Society of Cardiology. All rights reserved.
AB - AimsThe objective of the present analysis was to systematically examine the effect of intracoronary bone marrow cell (BMC) therapy on left ventricular (LV) function after ST-segment elevation myocardial infarction in various subgroups of patients by performing a collaborative meta-analysis of randomized controlled trials.Methods and resultsWe identified all randomized controlled trials comparing intracoronary BMC infusion as treatment for ST-segment elevation myocardial infarction. We contacted the principal investigator for each participating trial to provide summary data with regard to different pre-specified subgroups [age, diabetes mellitus, time from symptoms to percutaneous coronary intervention, infarct-related artery, LV end-diastolic volume index (EDVI), LV ejection fraction (EF), infarct size, presence of microvascular obstruction, timing of cell infusion, and injected cell number] and three different endpoints [change in LVEF, LVEDVI, and LV end-systolic volume index (ESVI)].Data from 16 studies were combined including 1641 patients (984 cell therapy, 657 controls). The absolute improvement in LVEF was greater among BMC-treated patients compared with controls: [2.55% increase, 95% confidence interval (CI) 1.83-3.26, P < 0.001]. Cell therapy significantly reduced LVEDVI and LVESVI (-3.17 mL/m2, 95% CI: -4.86 to -1.47, P < 0.001; -2.60 mL/m2, 95% CI -3.84 to -1.35, P < 0.001, respectively). Treatment benefit in terms of LVEF improvement was more pronounced in younger patients (age <55, 3.38%, 95% CI: 2.36-4.39) compared with older patients (age ≥55 years, 1.77%, 95% CI: 0.80-2.74, P = 0.03). This heterogeneity in treatment effect was also observed with respect to the reduction in LVEDVI and LVESVI. Moreover, patients with baseline LVEF <40% derived more benefit from intracoronary BMC therapy. LVEF improvement was 5.30%, 95% CI: 4.27-6.33 in patients with LVEF <40% compared with 1.45%, 95% CI: 0.60 to 2.31 in LVEF ≥40%, P < 0.001. No clear interaction was observed between other subgroups and outcomes.ConclusionIntracoronary BMC infusion is associated with improvement of LV function and remodelling in patients after ST-segment elevation myocardial infarction. Younger patients and patients with a more severely depressed LVEF at baseline derived most benefit from this adjunctive therapy. Published on behalf of the European Society of Cardiology. All rights reserved.
KW - Bone marrow cells
KW - Meta-analysis
KW - ST-segment elevation myocardial infarction
KW - Ventricular function
UR - http://www.scopus.com/inward/record.url?scp=84898992845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898992845&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/eht372
DO - 10.1093/eurheartj/eht372
M3 - Article
C2 - 24026778
AN - SCOPUS:84898992845
SN - 0195-668X
VL - 35
SP - 989
EP - 998
JO - European heart journal
JF - European heart journal
IS - 15
ER -